Clinical trial · Observational
Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)
A Non-interventional Study to Assess the Safety and Efficacy of First Line Therapy With Vectibix® in Combination With FOLFIRI or FOLFOX and to Validate a Prognostic Score in Adult Patients With RAS Wild-type Metastatic Colorectal Cancer in a Real World Setting (VALIDATE)
NCT03043950CI-TRIAL-00076435VALIDATEcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A safety and efficacy study of first line therapy with Vectibix® in combination with FOLFIRI or FOLFOX to validate a prognostic score in adult patients with RAS wild-type metastatic colorectal cancer in a real world setting (VALIDATE)
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| RAS Wild-type | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Panitumumab | Drug | Panitumumab | ALIAS |
Design
Arms and outcomes
Arms (3)
- label
- low risk
- description
- Low risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
- interventionNames
- Drug: Panitumumab
- label
- medium risk
- description
- Medium risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
- interventionNames
- Drug: Panitumumab
- label
- high risk
- description
- High risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
- interventionNames
- Drug: Panitumumab
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Eligibility according to current SmPC * Signed written informed consent * Diagnosis of RAS-WT mCRC * No prior systemic therapy in the palliative setting * Aged 18 years or older Exclusion Criteria: * Any contraindication according to current SmPC * Participation in other clinical trials
References
Publications (0)
Data not yet available
No reference posted for this study.